EGFR and non-small cell lung carcinoma: Monotherapy using first‐generation of EGFR‐TKIs can result in a 67%–88% intracranial objective response rate in EGFR‐TKI‐naïve EGFR‐mutant NSCLC patients.5, 8, 9